BR9708343A - Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit - Google Patents

Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit

Info

Publication number: BR9708343A
Authority: BR; Brazil
Prior art keywords: erbb3; kit; determining; erbb3 protein; cell line
Prior art date: 1996-03-27

Application number

BR9708343A

Other languages

English (en)

Inventor

Robert Akita

Mark Sliwkowski

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-27

Filing date

1997-03-07

Publication date

1999-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24500380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9708343(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-07 Application filed by Genentech Inc filed Critical Genentech Inc

1999-08-03 Publication of BR9708343A publication Critical patent/BR9708343A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Apparatus For Radiation Diagnosis (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)

BR9708343A 1996-03-27 1997-03-07 Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit BR9708343A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62403696A	1996-03-27	1996-03-27
PCT/US1997/003546 WO1997035885A1 (en)	1996-03-27	1997-03-07	ErbB3 ANTIBODIES

Publications (1)

Publication Number	Publication Date
BR9708343A true BR9708343A (pt)	1999-08-03

Family

ID=24500380

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9708343A BR9708343A (pt)	1996-03-27	1997-03-07	Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit

Country Status (15)

Country	Link
EP (2)	EP1728802A3 (pt)
JP (1)	JP3925943B2 (pt)
CN (1)	CN1214044C (pt)
AT (1)	ATE342283T1 (pt)
AU (1)	AU727082B2 (pt)
BR (1)	BR9708343A (pt)
CA (1)	CA2246429C (pt)
DE (1)	DE69736806T3 (pt)
DK (1)	DK0896586T4 (pt)
ES (1)	ES2274537T5 (pt)
IL (2)	IL126303A (pt)
NZ (1)	NZ331360A (pt)
PT (1)	PT896586E (pt)
WO (1)	WO1997035885A1 (pt)
ZA (1)	ZA972554B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6417168B1 (en) *	1998-03-04	2002-07-09	The Trustees Of The University Of Pennsylvania	Compositions and methods of treating tumors
AUPQ105799A0 (en) *	1999-06-18	1999-07-08	Victor Chang Cardiac Research Institute, The	Cell growth inhibition
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
TR200200472T2 (tr)	1999-08-27	2002-06-21	Genentech, Inc.	Anti-Erb B2 antikorları ile tedavi için dozajlar
EP1283053A1 (en) *	2001-08-09	2003-02-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibitors of HER3 activity
AU2008200654B2 (en) *	2001-08-09	2010-04-29	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Inhibitors of HER3 activity
CN100424175C (zh)	2002-03-26	2008-10-08	上海泽生科技开发有限公司	ErbB-3 用于肿瘤治疗的方法和组合物
JP5069843B2 (ja)	2002-07-15	2012-11-07	ジェネンテック，インコーポレイテッド	抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
EP1753463A2 (en)	2004-06-01	2007-02-21	Genentech, Inc.	Antibody drug conjugates and methods
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7521541B2 (en)	2004-09-23	2009-04-21	Genetech Inc.	Cysteine engineered antibodies and conjugates
AR056857A1 (es)	2005-12-30	2007-10-24	U3 Pharma Ag	Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2518508A1 (en)	2006-11-28	2012-10-31	U3 Pharma GmbH	Activated HER3 as a marker for predicting therapeutic efficacy
ES2631727T3 (es)	2007-02-16	2017-09-04	Merrimack Pharmaceuticals, Inc.	Anticuerpos contra el ErbB3 y usos de los mismos
UA104868C2 (uk) *	2008-08-15	2014-03-25	Меррімак Фармасьютікалз, Інк.	Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
JP5587975B2 (ja)	2009-04-07	2014-09-10	ロシュグリクアートアクチェンゲゼルシャフト	二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
CN105999263B (zh)	2009-11-13	2021-06-29	第一三共欧洲有限公司	用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
JP6184695B2 (ja)	2009-12-04	2017-08-23	ジェネンテック，インコーポレイテッド	多重特異性抗体、抗体アナログ、組成物、及び方法
CN102822201B (zh) *	2009-12-22	2014-09-24	罗切格利卡特公司	抗her3抗体及其用途
EP2544680B1 (en)	2010-03-11	2015-01-14	Merrimack Pharmaceuticals, Inc.	Use of erbb3 inhibitors in the treatment of triple negative breast cancer
BR112012025730B1 (pt) *	2010-04-09	2020-12-08	Aveo Pharmaceuticals, Inc	anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
JP6320753B2 (ja)	2010-05-27	2018-05-09	ゲンマブエー／エス	Ｈｅｒ２に対するモノクローナル抗体
WO2011147982A2 (en)	2010-05-27	2011-12-01	Genmab A/S	Monoclonal antibodies against her2 epitope
UY33498A (es)	2010-07-09	2013-01-03	Sanofi Aventis	Combinaciones de inhibidores de quinasas para el tratamiento de cancer
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
MX348637B (es) *	2010-11-01	2017-06-22	Symphogen As	Anticuerpos y composiciones anti-her3.
KR101517320B1 (ko)	2011-04-19	2015-05-28	메리맥 파마슈티컬즈, 인크.	단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
AU2012245116A1 (en)	2011-04-20	2013-11-07	Genmab A/S	Bispecific antibodies against HER2 and CD3
MX357391B (es)	2011-09-30	2018-07-06	Regeneron Pharma	Anticuerpos anti-erbb3 y usos de los mismos.
US9273143B2 (en)	2011-09-30	2016-03-01	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
CN103959065B (zh)	2011-10-06	2018-07-17	Aveo制药公司	预测肿瘤对抗erbb3抗体的应答
WO2013053076A1 (en)	2011-10-10	2013-04-18	Zensun （Shanghai）Science & Technology Limited	Compositions and methods for treating heart failure
EP2788377B1 (en) *	2011-11-09	2019-01-23	The UAB Research Foundation	Her3 antibodies and uses thereof
ES2745684T3 (es)	2011-11-23	2020-03-03	Medimmune Llc	Moléculas de unión específicas para HER3 y usos de las mismas
WO2013084147A2 (en) *	2011-12-05	2013-06-13	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
MX2015005756A (es) *	2012-11-08	2015-09-16	Hoffmann La Roche	Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4.
JP6302476B2 (ja)	2012-11-08	2018-03-28	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｅｒ３のベータヘアピンに結合するｈｅｒ３抗原結合タンパク質
US9180185B2 (en)	2013-01-11	2015-11-10	Hoffman-La Roche Inc.	Combination therapy of anti-HER3 antibodies
US11305012B2 (en)	2013-09-24	2022-04-19	Medimmune, Llc	Binding molecules specific for HER3 and uses thereof
WO2015100459A2 (en)	2013-12-27	2015-07-02	Merrimack Pharmaceuticals, Inc.	Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10745490B2 (en)	2014-04-11	2020-08-18	Celldex Therapeutics, Inc.	Anti-ErbB antibodies and methods of use thereof
EP3143048B1 (en)	2014-05-14	2019-08-28	F. Hoffmann-La Roche AG	Anti-her3 antibodies binding to the beta-hairpin of her3
US10184006B2 (en)	2015-06-04	2019-01-22	Merrimack Pharmaceuticals, Inc.	Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
TW202227504A (zh) *	2020-10-15	2022-07-16	大陸商上海翰森生物醫藥科技有限公司	抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5183884A (en) *	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
AU662311B2 (en) *	1991-02-05	1995-08-31	Novartis Ag	Recombinant antibodies specific for a growth factor receptor
EP1514934B1 (en) *	1992-02-06	2008-12-31	Novartis Vaccines and Diagnostics, Inc.	Biosynthetic binding protein for cancer marker
AU4025193A (en) *	1992-04-08	1993-11-18	Cetus Oncology Corporation	Humanized C-erbB-2 specific antibodies
AU6527894A (en) *	1993-03-30	1994-10-24	Trustees Of The University Of Pennsylvania, The	Prevention of tumors with monoclonal antibodies against (neu)
US5783186A (en) *	1995-12-05	1998-07-21	Amgen Inc.	Antibody-induced apoptosis

1997
- 1997-03-07 IL IL12630397A patent/IL126303A/en not_active IP Right Cessation
- 1997-03-07 WO PCT/US1997/003546 patent/WO1997035885A1/en not_active Ceased
- 1997-03-07 BR BR9708343A patent/BR9708343A/pt not_active Application Discontinuation
- 1997-03-07 JP JP53441197A patent/JP3925943B2/ja not_active Expired - Lifetime
- 1997-03-07 AT AT97908923T patent/ATE342283T1/de active
- 1997-03-07 ES ES97908923.2T patent/ES2274537T5/es not_active Expired - Lifetime
- 1997-03-07 IL IL12630397D patent/IL126303A0/xx unknown
- 1997-03-07 NZ NZ331360A patent/NZ331360A/xx not_active IP Right Cessation
- 1997-03-07 EP EP06014174A patent/EP1728802A3/en not_active Withdrawn
- 1997-03-07 EP EP97908923.2A patent/EP0896586B2/en not_active Expired - Lifetime
- 1997-03-07 DE DE69736806.8T patent/DE69736806T3/de not_active Expired - Lifetime
- 1997-03-07 DK DK97908923.2T patent/DK0896586T4/en active
- 1997-03-07 AU AU20711/97A patent/AU727082B2/en not_active Expired
- 1997-03-07 CN CNB971933588A patent/CN1214044C/zh not_active Expired - Lifetime
- 1997-03-07 PT PT97908923T patent/PT896586E/pt unknown
- 1997-03-07 CA CA002246429A patent/CA2246429C/en not_active Expired - Lifetime
- 1997-03-25 ZA ZA972554A patent/ZA972554B/xx unknown

Also Published As

Publication number	Publication date
DE69736806T3 (de)	2015-10-08
CN1214044C (zh)	2005-08-10
AU2071197A (en)	1997-10-17
DE69736806D1 (de)	2006-11-23
EP0896586A1 (en)	1999-02-17
PT896586E (pt)	2007-01-31
DK0896586T3 (da)	2007-02-19
ES2274537T5 (es)	2015-09-14
EP1728802A2 (en)	2006-12-06
EP0896586B1 (en)	2006-10-11
CN1214695A (zh)	1999-04-21
EP0896586B2 (en)	2015-05-20
JP3925943B2 (ja)	2007-06-06
DK0896586T4 (en)	2015-08-24
ZA972554B (en)	1998-09-25
DE69736806T2 (de)	2007-08-09
IL126303A0 (en)	1999-05-09
CA2246429A1 (en)	1997-10-02
ES2274537T3 (es)	2007-05-16
ATE342283T1 (de)	2006-11-15
CA2246429C (en)	2007-07-24
IL126303A (en)	2002-05-23
EP1728802A3 (en)	2006-12-13
JP2000508526A (ja)	2000-07-11
NZ331360A (en)	2000-03-27
WO1997035885A1 (en)	1997-10-02
AU727082B2 (en)	2000-11-30

Publication	Publication Date	Title
BR9708343A (pt)	1999-08-03	Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit
ATE412432T1 (de)	2008-11-15	Internalisierende erbb2 antikörper
EP0930366A3 (en)	1999-07-28	Binding domains in delta proteins
ATE213507T1 (de)	2002-03-15	Methode zur bindung von material an das beta- amyloid-peptid
DE69619493D1 (de)	2002-04-04	Polypeptid-dendrimer komplexe
DE60334141D1 (de)	2010-10-21	VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
PT1135498E (pt)	2008-04-30	Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
AU2152299A (en)	1999-05-24	Multivalent antigen-binding proteins
WO2002090983A3 (de)	2003-09-12	Quantitaver einschritt immuntest in lyophilisierter form
ATE169409T1 (de)	1998-08-15	Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung
IL154000A (en)	2010-02-17	A method that uses antibodies to diagnose arthritis
ATE217086T1 (de)	2002-05-15	Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
WO2023060278A3 (en)	2023-07-06	Tibtech methods and compositions for detecting cdh17
ATE48037T1 (de)	1989-12-15	Verfahren und reagenz zur verwendung zur bestimmung von pivka-ii.
NZ336781A (en)	2002-10-25	Fibronectin binding protein compositions, antibodies thereto, and methods of use
WO1999025734A3 (en)	1999-07-15	Th2 CELL DEPLETION; COMPOSITIONS; METHODS
AU5326198A (en)	1998-06-29	Synthetic biepitope compounds which can be used as standards in the biological assays of troponin I
AU2726388A (en)	1989-07-05	Determination method, use and components
CA2589421A1 (en)	1997-10-02	Erbb3 antibodies
WO1999024835A3 (en)	1999-07-22	An immunoassay for procollagen-iii-c-terminal propeptide
DE69220863D1 (de)	1997-08-21	Denaturierte transportproteine zur verbesserung von enzymgebundenen immunoassays (elisa)
Xu	1996	The interaction of phosphorylase kinase with glycogen phosphorylase.
DK0889907T3 (da)	2004-10-18	Monoklonale antistoffer, som binder humant væksthormon (hGH)
GB2333295A (en)	1999-07-21	Modified protein G and fragments thereof
HUP0003029A2 (hu)	2000-12-28	Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date	Code	Title	Description
2004-07-20	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: SUSPENSAO DO ANDAMENTO DO PEDIDO DE PATENTE PARA QUE SEJA COMPLEMENTADA A RETRIBUICAO EQUIVALENTE AO PEDIDO DE EXAME DE 36 (TRINTA E SEIS) REIVINDICACOES, VISTO QUE A RETRIBUICAO PAGA ATRAVES DA PETICAO N SP003288, DE 20000131, REFERE-SE A 21 (VINTE E UMA) REIVINDICACOES.
2006-01-17	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-04-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2008-02-06	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-02-10	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: DE ACORDO COM O ART. 37 DA LEI 9.279/96, INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTS. 24 E 25 DA LEI NO 9.279/96
2012-05-02	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.